New technology will address one of the leading causes of death worldwide
Sioux Falls, SD – February 18, 2025 – Exit 156 is proud to announce a $2.0 Million investment in Vail Scientific Inc., a pioneering company based in Minneapolis, Minnesota developing a diagnostic tool for screening patients suspected of having sepsis as an aid in triage. This investment will accelerate Vail Scientific’s development of its groundbreaking VSNOTM technology, which allows for real-time, non-invasive, and point-of-care screening of patients suspected of having sepsis.
Sepsis is a leading cause of death in hospitals globally and improved screening tools as part of patient triage can lead to earlier diagnosis. According to recent studies in the Lancet, 1 in 5 deaths worldwide is linked to sepsis, and, according to the NIH, nearly one quarter of sepsis cases treated are hospital-acquired.
“We are excited to support Vail Scientific in its mission to transform healthcare,” said Josh Robinson, Managing Partner at Exit 156. “Their innovative and groundbreaking approach to rapid sepsis screening is set to be the new standard of care, and we’re confident this investment will significantly enhance patient care.”
Vail Scientific is on a mission to aid in the early screening of patients with suspected sepsis with its groundbreaking technology. By aiding in the rapid screening of sepsis as part of the patient triage, Vail’s innovation has the potential to enhance patient care through more rapid sepsis diagnosis. Now, with the support of Exit 156, Vail is accelerating its journey—expanding clinical trials, advancing toward FDA clearance and commercialization of this novel screening diagnostic tool.
“We are thrilled to partner with Exit 156 to take our technology to the next level,” said Tom Burke, CEO of Vail Scientific. “This funding will enable us to expand our clinical trials and bring to market faster and enhance patient care.”
About Exit 156
Exit 156 is an investment firm focused on aligning distinctive, growth-oriented investment prospects with exceptional financial acumen and their network of operating partners. They specialize in small and middle-market businesses in healthcare services, devices, and
technology. exit156.com
About Vail Scientific
Vail Scientific was established by four founders with over eight decades of combined industry experience in medical technology and healthcare. The company is pioneering the development of VSNOTM sepsis screening technology that hopes to provide rapid, non-invasive additional screen at the point of care, helping healthcare providers treat patients more quickly and effectively. vailscientific.com
For media inquiries, please contact:
Josh Robinson
Josh@exit156.com
The information contained herein may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements may be identified through the use of words such as “may”, “expects/excepted”, “will”, “anticipates”, “allows”, “estimates”, “believes”, “provides” or by statements indicating certain actions “may”, “could”, “should” or “might” occur. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The information contained herein was current as of the date prepared and we specifically disclaim any obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise.